Unicycive Therapeutics, Inc.

As of November 14, 2023, Unicycive Therapeutics, Inc. is considered overvalued with a valuation downgrade to "does not qualify," reflected by a Price to Book Value of 8.07, a negative EV to EBIT of -2.32, and a concerning ROE of -315.28%, indicating severe operational inefficiencies compared to its peers.

As of June 20, 2025, the trend is bullish with strong indicators like MACD and Bollinger Bands supporting this view, although the RSI shows some bearish signals indicating potential weakness in momentum.

Unicycive Therapeutics, Inc. is a micro-cap company in the miscellaneous industry, recently reporting a net profit of $1 million for Q1 2025, with a market cap of $82.84 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -315.28%.

As of Jun 18, Unicycive Therapeutics, Inc. has a market capitalization of 82.84 million, with net sales of 0.00 million and a net profit of -21.18 million over the last four quarters. The company's shareholder's funds are 7.43 million, and total assets are 31.67 million.